Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
NCT ID: NCT02065297
Last Updated: 2019-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
143 participants
OBSERVATIONAL
2009-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participation consists in taking one or several blood samples depending on the group patients/controls.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Cellular Heterogeneity in Patients With Mastocytosis
NCT06432556
In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells
NCT00731705
Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment
NCT00499070
Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03357172
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
NCT04494061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Horton's disease
2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
Infectious disease
1 blood sample
Neoplasia
1 blood sample
Control
1 blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1 blood sample
2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have provided written informed consent
* Patients with national health insurance cover
* Age: 50 to 90 years
Patients with Horton' s disease :
* at the diagnosis, before any treatment
* or in remission
* or in relapse
Patients with an infectious disease :
* Bacteriologically or radiologically confirmed
* Presenting an inflammatory syndrome defined by :
* CRP ≥ 10 mg / L
* and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1
Patients with neoplasia ( solid tumour or hemopathy ) :
* At the diagnosis, before treatment by chemotherapy
* Presenting an inflammatory syndrome defined by:
* CRP ≥ 10 mg / L
* and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1
Controls :
These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD ( Champmaillot centre for geriatric patients ) and patients without infectious, inflammatory, or auto-immune disease ( CRP \< 5mg / L ) or cancer recruited from the investigating departments of Dijon CHU. They will be matched for age and sex.
* Age: 18 - 90 years
* Patients with national health insurance cover
* who have provided written informed consent
* Absence of an inflammatory syndrome ( CRP \< 5 mg / L )
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de BESANCON
Besançon, , France
CHU de DIJON
Dijon, , France
CH de METZ
Metz, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUDIA-SAMSON HORTON TH17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.